Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01064921 · ClinicalTrials.gov registry record · Phase 1
Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell Carcinoma
A Phase 1 study of Stage III Squamous Cell Carcinoma of the Oropharynx and Stage IV Squamous Cell Carcinoma of the Oropharynx, sponsored by Ohio State University Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
- 1
- Study location
NCT01064921 is a Phase 1 study of Stage III Squamous Cell Carcinoma of the Oropharynx and Stage IV Squamous Cell Carcinoma of the Oropharynx that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 27 participants, below the 154-participant average among 4 other Stage III Squamous Cell Carcinoma of the Oropharynx trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01064921, a Phase 1 study of Stage III Squamous Cell Carcinoma of the Oropharynx and Stage IV Squamous Cell Carcinoma of the Oropharynx, has completed, sponsored by Ohio State University Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells. Giving vorinostat together with chemotherapy and radiation therapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vorinostat when given together with cisplatin and radiation therapy in treating patients with stage III or stage IVa squamous cell cancer of the oropharynx which is either unresectable or borderline resectable.
Conditions Studied
Interventions
- DRUG cisplatin
- DRUG vorinostat
- RADIATION radiation therapy
- PROCEDURE Correlative Studies
Study Locations (1)
Ohio
- The Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2010-01-19 |
| Est. Completion | 2017-11-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01064921
The ClinicalTrials.gov registry entry for NCT01064921 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 154-participant average among 4 other Stage III Squamous Cell Carcinoma of the Oropharynx trials with a reported enrollment target (82% lower). The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Stage III Squamous Cell Carcinoma of the Oropharynx appearing as the primary indexed condition, and to 4 interventions - of which cisplatin is the first listed.
NCT01064921 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT01064921 about?
NCT01064921 is a clinical study titled "Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell Carcinoma". RATIONALE: Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy u...
What is the current status of trial NCT01064921?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2010-01-19. Estimated completion is 2017-11-08.
What conditions does trial NCT01064921 study?
This clinical trial studies the following conditions: Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx.
What interventions are being tested in trial NCT01064921?
The interventions under investigation include: cisplatin (DRUG), vorinostat (DRUG), radiation therapy (RADIATION), Correlative Studies (PROCEDURE).
Who is sponsoring clinical trial NCT01064921?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01064921 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage III Squamous Cell Carcinoma of the Oropharynx
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer
COMPLETED · Phase 1
-
Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Freeze-Dried Black Raspberries in Preventing Oral Cancer Recurrence in High At-Risk Appalachian Patients Oral Cancer Survivors
COMPLETED · NA
-
Paclitaxel and Carboplatin Before Radiation Therapy With Paclitaxel in Treating HPV-Positive Patients With Stage III-IV Oropharynx, Hypopharynx, or Larynx Cancer
COMPLETED · Phase 2
Explore more on PlainTrial
Stage III Squamous Cell Carcinoma of the Oropharynx
All registered trials for this condition
Stage IV Squamous Cell Carcinoma of the Oropharynx
All registered trials for this condition
Ohio
All trials with a study site in Ohio
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.